Q-omics provides the consensus-scored STAG3L5P-PVRIG2P-PILRB profile across patient tissues and cancer cell-line models. STAG3L5P-PVRIG2P-PILRB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, STAG3L5P-PVRIG2P-PILRB is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, STAG3L5P-PVRIG2P-PILRB RNA expression shows 17,411 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where STAG3L5P-PVRIG2P-PILRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAG3L5P-PVRIG2P-PILRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAG3L5P-PVRIG2P-PILRB survival associations across molecular data types. STAG3L5P-PVRIG2P-PILRB RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAG3L5P-PVRIG2P-PILRB RNA expression–survival associations across cancer types. High STAG3L5P-PVRIG2P-PILRB expression shows unfavorable associations in KICH, ACC, KIRC, COAD and LGG, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for STAG3L5P-PVRIG2P-PILRB RNA expression.
This table summarizes STAG3L5P-PVRIG2P-PILRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for STAG3L5P-PVRIG2P-PILRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAG3L5P-PVRIG2P-PILRB shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, HNSC and STAD. The KIRC box plot shows higher STAG3L5P-PVRIG2P-PILRB RNA expression in tumor versus normal tissue (log2 FC = +0.576, t-test p < 0.001).
This table shows molecular features associated with STAG3L5P-PVRIG2P-PILRB in patient tissues and cancer cell lines. In patient samples, STAG3L5P-PVRIG2P-PILRB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STAG3L5P-PVRIG2P-PILRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
